# A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

> **NCT00561743** · PHASE2 · COMPLETED · sponsor: **Janssen-Ortho Inc., Canada** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone

## Key facts

- **NCT ID:** NCT00561743
- **Lead sponsor:** Janssen-Ortho Inc., Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561743, "A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00561743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*